Results 21 to 30 of about 43,704 (225)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Cell Death and Disease, 2022
Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects ...
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao, Samuel Waxman, Yongkui Jing   +7 more
doaj   +1 more source

Third cranial nerve palsy: An unusual presentation of cytarabine toxicity

TNOA Journal of Ophthalmic Science and Research, 2023
A 62-year-old male presented with pupil-sparing third cranial nerve palsy. He was not a known case of diabetes mellitus or hypertension. The patient was on cytarabine as a part of treatment for acute lymphoblastic leukaemia (ALL).
Suchismita Mishra, Pradeep K Panigrahi, Yamijala N Srija, Priyanka Samal   +3 more
doaj   +1 more source

Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia

Cancer Reports, 2023
Background and Aim Different studies have shown pharmacogenetic variants related to drug toxicity in acute myeloid leukemia (AML) patients. Our aim was to identify the association between ABCB1, CDA, DCK, GSTT1, and GSTM1 variants with clinical outcomes ...
Luz K. Yunis, Adriana Linares‐Ballesteros, Nelson Aponte, Gisela Barros, Johnny García, Laura Niño, Gloria Uribe, Edna Quintero, Juan J. Yunis   +8 more
doaj   +1 more source

Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications

mBio, 2018
Oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically linked to primary effusion lymphoma (PEL), an aggressive and nontreatable malignancy commonly found in AIDS patients.
Marion Gruffaz, Shenghua Zhou, Karthik Vasan, Teresa Rushing, Qing Liu Michael, Chu Lu, Jae U. Jung, Shou-Jiang Gao   +7 more
doaj   +1 more source

Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13

BioTechniques, 2022
Acute myeloid leukemia patients with FMS-like tyrosine kinase 3–internal tandem duplications and mixed lineage leukemia–protein AF9 fusion proteins suffer from poor clinical outcomes.
Subhash C Prajapati, Nicholas Dunham, Hao Fan, Francine E Garrett-Bakelman   +3 more
doaj   +1 more source

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

Frontiers in Pharmacology, 2022
To date, only few marine natural compounds have been proved to be active in breast cancer (BC). The main marine-derived drugs that have been studied for the treatment of BC are tubulin-binding agents (eribulin and plocabulin), DNA-targeting agents ...
Rita De Sanctis, Rita De Sanctis, Flavia Jacobs, Flavia Jacobs, Chiara Benvenuti, Chiara Benvenuti, Mariangela Gaudio, Mariangela Gaudio, Raul Franceschini, Richard Tancredi, Paolo Pedrazzoli, Paolo Pedrazzoli, Armando Santoro, Armando Santoro, Alberto Zambelli, Alberto Zambelli   +15 more
doaj   +1 more source

Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America

Hematology, 2022
Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America.
Andrés Gómez-De León, Roberta Demichelis-Gómez, Alfredo Pinedo-Rodríguez, Daniel Enriquez-Vera, Juan Antonio Flores-Jiménez, Adrián Alejandro Ceballos-López, Margarita Rodríguez-Mejorada, Miguel Angel Herrera Riojas, Roberto Ovilla-Martínez, Pamela Báez-Islas, Xóchitl Cota-Rangel, Yvette Neme-Yunes, Sergio Inclán-Alarcón, Nelson J. López-Flores, Perla R. Colunga-Pedraza, Anna C. Rodríguez-Zúñiga, David Gómez-Almaguer   +16 more
doaj   +1 more source

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

BMC Cancer, 2018
Background The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance.
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, Sara Ek   +8 more
doaj   +1 more source

The histological changes induced by cytarabine on rabbits kidneys (with and without vitamin E administration) [PDF]

Iraqi Journal of Veterinary Sciences, 2019
The present study was designed to determine the histological changes induced by Cytarabine drug on the structure of rabbits kidneys and the protective effects of vitamin E on these histological changes.
Saif Al-Jammas, ayad Al-Sarraj
doaj   +1 more source

The histological changes induced by Cytarabine on rabbits livers (with and without vitamin E administration) [PDF]

Iraqi Journal of Veterinary Sciences, 2020
The present study was intended to determine the histological changes induced by Cytarabine drug on the structure of rabbit's livers and the protective effects of vitamin E on these histological changes.
Saif Al-Jammas, Ayad Al-Saraj
doaj   +1 more source